Medtronic beats consensus with strong sales
This article was originally published in Clinica
Executive Summary
Medtronic exceeded analysts’ expectations for its first fiscal quarter of 2010 with revenue growth from each of its medical device businesses. Group revenue for the period, which was up 6% at $3.9bn, benefited from sales growth in the firm’s cardiac rhythm disease management (CRDM), spinal, cardiovascular, neuromodulation and diabetes segments.